Reference : Recommendations for an update of the 2010 European regulatory guideline on clinical i...
Scientific journals : Article
Human health sciences : General & internal medicine
http://hdl.handle.net/2268/189709
Recommendations for an update of the 2010 European regulatory guideline on clinical investigation of medical products used in the treatment of osteoarthritis and reflections about related clinically relevant outcomes: expert consensus statement.
English
Reginster, Jean-Yves mailto [Université de Liège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé >]
REITER-NIESERT, S. []
Bruyère, Olivier mailto [Université de Liège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé >]
BERENBAUM, F. []
BRANDI, M.L. []
BRANCO, J. []
DEVOGELAER, J.P. []
HERRERO-BAUMONT, G. []
KANIS, J. []
MAGGI, S []
MAHEU, E. []
RICHETTE, P. []
RIZZOLI, R. []
COOPER, C []
2015
Osteoarthritis and Cartilage
W.B. Saunders
23
2086-2093
Yes (verified by ORBi)
International
1063-4584
1522-9653
London
United Kingdom
[en] Osteoarthritis ; Registration of drugs ; Guideline
[en] Objective: The European Society on Clinical and Economic aspects of Osteoporosis and Osteoarthritis
(ESCEO) organised a working group to evaluate the need for updating the current European guideline on
clinical investigation of drugs used in the treatment of osteoarthritis (OA).
Design: Areas of potential attention were identified and the need for modifications, update or clarification
was examined. Proposals were then developed based on literature reviews and through a
consensus process.
Results: It was agreed that the current guideline overall still reflects the current knowledge in OA,
although two possible modifications were identified. The first relates to the number and timing of
measurements required as primary endpoints during clinical trials of symptom-relieving drugs, either
drugs with rapid onset of action or slow acting drugs. The suggested modifications are intended to take
into consideration the time related clinical need and expected time response to these drugs e i.e., a more
early effect for the first category in addition to the maintenance of effect, a more continuous benefit over
the long-term for the latter e in the timing of assessments.
Secondly, values above which a benefit over placebo should be considered clinically relevant were
considered. Based on literature reviews, the most consensual values were determined for primary
endpoints of both symptom-relieving drugs (i.e., pain intensity on a visual analogue scale (VAS)) and
disease-modifying drugs (i.e., radiographic joint-space narrowing).
http://hdl.handle.net/2268/189709
10.1016/j.joca.2015.07.001

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Recommendations for an update of the 2010 European regulatory guideline on clinical investigation of medicinal products used in treatment of osteoarthritis and reflections about related clinically relevant outcomes ex.pdfPublisher postprint194.96 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.